Compugen Stock Price, News & Analysis

Compugen (NASDAQ: CGEN) reported Q2 2025 financial results and provided corporate updates. The company dosed its first patient in the MAIA-ovarian platform trial evaluating COM701 as maintenance therapy for platinum-sensitive ovarian cancer. Revenue was $1.3 million, down from $6.7 million in Q2 2024, with a net loss of $7.3 million.

The company maintains a strong financial position with $93.9 million in cash and equivalents, expected to fund operations into 2027. Partner AstraZeneca is advancing rilvegostomig with ten active Phase 3 trials, with upcoming data presentations at ESMO 2025. Additionally, Compugen will present pooled analysis from three Phase 1 trials of COM701 in platinum-resistant ovarian cancer at ESMO 2025.

The company announced leadership changes, with Dr. Eran Ophir taking over as CEO and current CEO Dr. Anat Cohen-Dayag transitioning to Executive Chair in September 2025.

Compugen (NASDAQ:CGEN) announced its upcoming presentation at ESMO 2025 in Berlin, Germany. The presentation will feature a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum resistant ovarian cancer patients.

The analysis includes data from trials testing COM701 as both monotherapy and combination therapy in heavily pretreated patients. Dr. Oladapo Yeku from Massachusetts General Hospital will present the findings on October 18, 2025 at 12:00-12:45 CEST. The poster presentation (#1196P) will subsequently be available on Compugen's website.

Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered drug target discovery, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Investors can access the call via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through Compugen's website. A replay will be available on the website after the live event.

Compugen (NASDAQ: CGEN) has announced the dosing of the first patient in its global randomized sub-trial 1 of the MAIA-ovarian adaptive platform trial. The study evaluates COM701, a potential first-in-class anti-PVRIG antibody, as maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer.

The trial is supported by strong biological evidence showing high PVRIG pathway expression in ovarian cancer. Previous clinical data demonstrated that COM701, in combination with PD-1 and TIGIT blockade, achieved durable responses in heavily pre-treated platinum-resistant ovarian cancer patients. An interim analysis is planned for the second half of 2026, with researchers considering a three-month improvement in progression-free survival over the six-month benchmark to be clinically meaningful.

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced upcoming presentations of its AI/ML-driven predictive computational research at two major scientific conferences. The first presentation will be at the 2025 Annual Congress of the European Association for Cancer Research in Lisbon, Portugal (June 16-19), focusing on predicting immune evasion and immunotherapy resistance in TNBC subtypes. The second presentation will take place at the International Society for Computational Biology conference in Liverpool, UK (July 20-24), addressing computational prediction of TNBC tumor subtypes using single cell atlas analysis. Both presentations highlight Compugen's expertise in using computational methods to understand complex cancer biology. The posters will be made available on Compugen's website after the presentations.

AstraZeneca and Daiichi Sankyo have initiated the DESTINY-Endometrial01 phase 3 trial for ENHERTU in first-line treatment of HER2 expressing primary advanced or recurrent endometrial cancer. The study will evaluate ENHERTU combined with rilvegostomig or pembrolizumab versus standard platinum-based chemotherapy with pembrolizumab. The trial targets patients with HER2 expressing (IHC 3+/2+), mismatch repair proficient endometrial cancer, a condition affecting 18-56% of cases with a median survival of up to 30 months in advanced stages. This initiative follows positive results from the DESTINY-PanTumor02 study, which led to tumor agnostic approval for ENHERTU in previously treated HER2 positive metastatic tumors. The trial represents a significant step in addressing the unmet need in endometrial cancer treatment, where no HER2 directed medicines are currently approved for first-line therapy.

AstraZeneca and Daiichi Sankyo reported promising results for DATROWAY (datopotamab deruxtecan) in treating non-small cell lung cancer (NSCLC) across three clinical trials presented at ASCO 2025. In TROPION-Lung02, the combination of DATROWAY with pembrolizumab showed a 54.8% objective response rate in the doublet arm and 55.6% in the triplet arm including chemotherapy. TROPION-Lung04 demonstrated a 57.5% response rate when combining DATROWAY with rilvegostomig. The NeoCOAST-2 trial showed encouraging results in early-stage NSCLC with a 35.2% pathologic complete response rate when combining DATROWAY with durvalumab and chemotherapy. Safety profiles were consistent with previous studies, with manageable adverse events including some cases of interstitial lung disease.

Compugen (NASDAQ: CGEN) reported its Q1 2025 financial results and corporate updates. The company initiated a platform trial of COM701 maintenance therapy for platinum-sensitive ovarian cancer patients and continues recruitment for GS-0321 Phase 1 trial. Partner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across various cancers. Financially, Compugen reported $103.7 million in cash with runway into 2027, $2.3 million in revenues, and a net loss of $7.2 million ($0.08 per share) for Q1 2025. The company announced key leadership changes effective September 2025, with current CEO Dr. Anat Cohen-Dayag becoming Executive Chair and CSO Dr. Eran Ophir assuming the CEO position.

Compugen (NASDAQ: CGEN) announced key leadership changes effective September 2025. Dr. Anat Cohen-Dayag, current President and CEO, will transition to Executive Chair of the Board of Directors, while Dr. Eran Ophir, current Chief Scientific Officer, will become President and CEO. Paul Sekhri will step down as Board Chair after 8 years. Under Dr. Cohen-Dayag's leadership since 2010, Compugen transformed into a therapeutic discovery company with an immuno-oncology pipeline powered by Unigen™, their AI/ML platform. The company's portfolio includes COM701, COM902, and partnerships with AstraZeneca and Gilead. Dr. Cohen-Dayag will focus on corporate strategy and strategic collaborations in her new role, while Dr. Ophir brings nearly a decade of experience at Compugen and has been instrumental in building the company's pipeline. The company maintains a strong financial position with cash runway into 2027.